NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Roche Holding AG
("Roche Holding") (OTC:RHHBY) between March 2, 2017 and June 5, 2017. You are hereby
notified that a securities class action lawsuit has been commenced in the United States District Court for the District of
New Jersey. To get more information go to:
http://www.zlk.com/pslra-sb/roche-holding-ag?wire=3
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than
Herceptin alone in preventing breast cancer; and (2) as a result, Defendants' statements about Roche Holding AG's business,
operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
If you suffered a loss in Roche Holding you have until August 7, 2017
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a
lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered
hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
